Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
| 2.34 | |
| 2.43 | |
| - | |
| 2.4347 | |
| 2.32 | |
| 0.94-6.42 | |
| 106 M | |
| 44 737 K | |
| 610 K | |
| -0.22 | |
| 1.936 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
The 2024 presidential election is shaping up to be just as exciting and contentious the 2020 contest. That’s because it looks to be a rematch between President Biden and former President Trump. Ther...
Investing.com -- U.S. stocks erased early gains and turned lower, weighed by concerns about higher for longer interest rates and the rising potential for a government shutdown this weekend. Here are ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
